Postmenopausal Osteoporosis Treatments
Find Postmenopausal Osteoporosis Treatments
Generic Name
Denosumab
Brand Names
Ospomyv, Jubbonti, Bomyntra, Xgeva, Osenvelt, Conexxence, Xtrenbo, Bosaya, Oziltus, Boncresa, Denosumab-BMWO, WYOST, ENOBY, Aukelso, Bilprevda, Stoboclo, Bildyos
FDA approval date: June 05, 2010
Classification: RANK Ligand Inhibitor
Form: Injection
What is Ospomyv (Denosumab)?
Enoby is a RANK ligand inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
A Phase 4 Single-arm Open-label Study for the Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China
Summary: The main objective of this study is to evaluate the efficacy of Prolia® in improving bone mass density (BMD) of lumbar spine at month 12.
Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults - A Randomised Controlled Trial
Summary: The Bone Zone trial is a prospective, multi-centre, double-blind, phase II, randomised controlled trial evaluating the effect of denosumab or zoledronic acid compared to placebo on change in bone mineral density over one year in women aged 50 years or older and men aged 70 years or older requiring admission to intensive care for greater than 24 hours. 450 women aged 50 years or older and men aged ...
Preserving Geriatric Muscle With an Osteoporosis Medication
Summary: Our goal is to demonstrate efficacy of the novel agent Denosumab to improve or preserve muscle health, strength, mobility and function in frail older adults.